<DOC>
	<DOCNO>NCT00724360</DOCNO>
	<brief_summary>This multicenter open-label phase II trial trastuzumab patient HER2 positive B-ALL relapse , refractory disease . Herceptin administer 4 mg/kg intravenous load dose follow 2 mg/kg weekly least 2 month and/or till progression . Response HER2 expression assess month bone marrow aspirate .</brief_summary>
	<brief_title>Trastuzumab HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia ( B-ALL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>age &gt; 18 year BALL relapse refractory BALLperformance status 02 Eastern Cooperative Oncology Group scale adequate hepatic renal function ( AST ALT &lt; = 5 time upper limit normal creatinine &lt; 2 time upper limit normal ) &gt; 20 % blast bone marrow , &gt; 30 % bone marrow blast population HER2 positive assess immunophenotyping Previous treatment trastuzumab FEVG &lt; 50 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>relapsed/refractory</keyword>
	<keyword>HER2</keyword>
	<keyword>positive</keyword>
	<keyword>B-ALL</keyword>
	<keyword>trastuzumab</keyword>
</DOC>